Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Christopher Lescinskas"'
Autor:
Rupa Narayan, Robert P. Hasserjian, Margaret C. Wey, Tanya T. Behnan, Meghan Bergeron, Jessica Rae, Mason L. Mann, Ashkan Emadi, Christina Bertoli, Eyal C. Attar, Traci M. Blonquist, Christopher Lescinskas, Jenna A. Moran, Yi-Bin Chen, Steven L. McAfee, Vu H. Duong, Patricia Lesho, Timothy A. Graubert, Jennifer Lombardi Story, Andrew M. Brunner, Meghan Burke, Megan K. Vartanian, Gabriela S. Hobbs, Tina T. Som, Donna Neuberg, Hanno Hock, Molly Macrae, Julia Foster, Kristin McGregor, Philip C. Amrein, Amir T. Fathi, Karen K. Ballen, Frederic I. Preffer, Aura Y. Ramos, Christine Connolly
Publikováno v:
Cancer. 126:1264-1273
Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high interest. Brentuximab vedotin (BV) is an antibody-drug conjugate that is specific for human
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::411429856bce3fe963798cabff48aa70
https://doi.org/10.1002/cncr.32657
https://doi.org/10.1002/cncr.32657
Autor:
Dian Wang, Katherine E Santoro, Christina L. Roland, Sonia Cohen, Gregory M. Cote, Beow Y. Yeap, Gunnlaugur P. Nielsen, Andrew J. Bishop, Edwin Choy, Christopher Lescinskas, Ivy A. Petersen, Alex B. Haynes, Sam S. Yoon, Yen-Lin Chen, John T. Mullen, Thomas F. DeLaney
Publikováno v:
Journal of Clinical Oncology. 39:11550-11550
11550 Background: RPS often have local recurrence (LR) after surgery. Preoperative radiation (RT) to 50.4 Gy can reduce LR risk but is not uniformly effective, especially after (+) margin resections. Therefore, we conducted a multi-institutional, pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::837a645db44378318339d1f8527710d0
https://doi.org/10.1200/jco.2021.39.15_suppl.11550
https://doi.org/10.1200/jco.2021.39.15_suppl.11550
Autor:
Karen K. Ballen, Steven L. McAfee, Meghan Bergeron, Robert P. Hasserjian, Meghan Burke, Mason L. Mann, Tanya T. Behnan, Aura Y. Ramos, Jennifer Lombardi Story, Vu H. Duong, Traci M. Blonquist, Philip C. Amrein, Hanno Hock, Kaitlyn M. Fishman, Gabriela S. Hobbs, Frederic I. Preffer, Andrew M. Brunner, Megan K. Vartanian, Molly Macrae, Christine Connolly, Ashkan Emadi, Christina Bertoli, Donna Neuberg, Patricia Lesho, Amir T. Fathi, Jenna A. Moran, Christopher Lescinskas, Kristin McGregor, Tina T. Som, Julia Foster
Publikováno v:
Blood. 132:1431-1431
Background: Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) consisting of an antibody specific for human CD30, an anti-microtubule agent monomethyl auristatin E (MMAE), and a protease-cleavable linker attaching MMAE to the antibody. BV i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3351a2f1884c3efd60d655ec03e099e8
https://doi.org/10.1182/blood-2018-99-115031
https://doi.org/10.1182/blood-2018-99-115031